Lead Product(s) : Arachis Hypogaea Allergen
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Palforzia® Gets Positive CHMP Opinion for Peanut Allergy in Toddlers
Details : Palforzia is in the U.S an oral immunotherapy treatment indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut for patients.
Product Name : Palforzia
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
December 02, 2024
Lead Product(s) : Arachis Hypogaea Allergen
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Forigerimod
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 2/3 Adaptive Clinical Trial of P140 (Lupuzor) in Lupus to Commence Following FDA Meeting
Details : Lupuzor (Forigerimod) have unique mechanism of action involves modulating the activation of auto-reactive T-cells, which is investigated for treatment of systemic lupus erythematosus.
Product Name : Lupuzor
Product Type : Peptide
Upfront Cash : Inapplicable
June 19, 2023
Lead Product(s) : Forigerimod
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Birch Pollen Extract
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Stallergenes Greer Initiates a European Paediatric Phase III Study With Staloral® Birch
Details : Staloral Staloral Birch is a sublingual solution of allergen extracts for AIT. It is indicated in the treatment of seasonal or perennial allergic rhinitis, rhino-conjunctivitis and mild to moderate allergic asthma
Product Name : Staloral Birch
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 25, 2023
Lead Product(s) : Birch Pollen Extract
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ravulizumab
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Prolonged results from Phase III CHAMPION-MG trial showed that Ultomiris demonstrated long-term efficacy in adults with AChR antibody-positive myasthenia gravis, with improvements in activities of daily living, muscle strength and quality of life, sustai...
Product Name : Ultomiris
Product Type : Antibody
Upfront Cash : Inapplicable
June 04, 2022
Lead Product(s) : Ravulizumab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tabelecleucel
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Atara Biotherapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Details : FUJIFILM will provide Atara with access to the flexible capacity and specific capability needed to manufacture clinical and commercial-stage allogeneic cell therapies for its promising pipeline, including tabelecleucel (tab-cel®), ATA188, and allogeneic...
Product Name : Tab-cel
Product Type : Cell and Gene therapy
Upfront Cash : $100.0 million
April 04, 2022
Lead Product(s) : Tabelecleucel
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Atara Biotherapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Ravulizumab
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Submission based on positive Phase III trial in which Ultomiris (Ravulizumab-cwvz) significantly improved functional activities as measured by Myasthenia Gravis-Activities of Daily Living Profile.
Product Name : Ultomiris
Product Type : Antibody
Upfront Cash : Inapplicable
December 21, 2021
Lead Product(s) : Ravulizumab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nomacopan
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Akari Therapeutics Open IND with FDA for Bullous Pemphigoid Treatment
Details : Akari Therapeutics have opened an investigational new drug application (IND) with the FDA for its multicentre Phase III study with nomacopan, for the treatment of moderate and severe bullous pemphigoid (BP).
Product Name : Coversin
Product Type : Protein
Upfront Cash : Inapplicable
December 04, 2021
Lead Product(s) : Nomacopan
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nomacopan
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Akari Therapeutics to Present Its Phase III Plans for Nomacopan in Patients with Bullous Pemphigoid
Details : The aim of the ARREST-BP Phase III trial is to assess the safety of nomacopan in BP patients, and to test nomacopan’s ability to rapidly control the symptoms of BP and reduce exposure to systemic steroids to potentially decrease steroid related morbidi...
Product Name : Coversin
Product Type : Protein
Upfront Cash : Inapplicable
October 09, 2021
Lead Product(s) : Nomacopan
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nomacopan
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nomacopan has potential to replace long term steroid treatment (standard of care) in BP, which has multiple adverse effects and increases mortality in this elderly and frail population.
Product Name : Coversin
Product Type : Protein
Upfront Cash : Inapplicable
April 28, 2021
Lead Product(s) : Nomacopan
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Anifrolumab
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The pivotal TULIP programme includes two Phase III clinical trials, TULIP 1 and TULIP 2, that evaluated the efficacy and safety of anifrolumab versus placebo in patients with moderately to severely active autoantibody-positive SLE who are receiving stand...
Product Name : Saphnelo
Product Type : Antibody
Upfront Cash : Inapplicable
March 06, 2021
Lead Product(s) : Anifrolumab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable